Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
To investigate whether a year of rasagiline may reduce the progression from idiopathic REM
sleep behavior disorder (RBD) to Parkinson's disease (PD).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Beijing Tiantan Hospital Fujian Medical University Union Hospital Guizhou Medical University Huashan Hospital Jiangsu Province Nanjing Brain Hospital Qilu Hospital of Shandong University Second Affiliated Hospital of Soochow University Sir Run Run Shaw Hospital The Affiliated Hospital of Hangzhou Normal University The First Affiliated Hospital of Anhui Medical University The First Affiliated Hospital of Dalian Medical University The First Affiliated Hospital of Guangzhou Medical University West China Hospital Xinhua Hospital, Shanghai Jiao Tong University School of Medicine